Tagrisso suitable for patients with disease progression to CNS metastases, data shows

6 June 2017

Tagrisso (osimertinib), the potential new standard-of-care for locally advanced or metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC), also shows efficacy in patients with disease progression to central nervous system (CNS) metastases, according to new evidence reported at ASCO 2017.

The findings from the Phase III AURA3 trial showed that the AstraZeneca (LSE: AZN) drug doubled the length of time patients with CNS metastases lived without disease worsening or death versus chemotherapy, with figures of 11.7 months compared to 5.6 months.

Marina-Chiara Garassino, from the Thoracic Oncology Unit, Medical Oncology Department Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, said: “The results of osimertinib in patients with CNS metastases are consistent with what has already been reported in the overall AURA3 population.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK